Amphastar Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Amphastar just signed a big deal, details TBD.

AI Summary

On October 21, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any associated parties or financial terms.

Why It Matters

This filing indicates a significant new contract or partnership for Amphastar Pharmaceuticals, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Registrant
• October 21, 2025 (date) — Date of earliest event reported
• October 24, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AMPH The Nasdaq Stock Mar

Filing Documents

• amph-20251021x8k.htm (8-K) — 53KB
• 0001297184-25-000058.txt ( ) — 163KB
• amph-20251021.xsd (EX-101.SCH) — 3KB
• amph-20251021_lab.xml (EX-101.LAB) — 15KB
• amph-20251021_pre.xml (EX-101.PRE) — 10KB
• amph-20251021x8k_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On October 21, 2025 (the "Effective Date") Amphastar Pharmaceuticals, Inc. ("Amphastar"), a wholly-owned subsidiary of Amphastar Pharmaceuticals, Inc. (the "Company"), and Nanjing Chengong Pharmaceutical Co., Limited ("Chengong"), a wholly-owned subsidiary of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin"), entered into a Distribution Agreement (the "Agreement") pursuant to which Amphastar and Chengong will collaborate to expand distribution of the Company's nasal powder product, BAQSIMI , in Mainland China, Taiwan, Hong Kong, and Macau in the Greater China region (the "Region"). Per the terms of the Agreement, Amphastar has appointed Chengong as the exclusive distributor to market and sell BAQSIMI in the Region. Chengong is responsible for obtaining any and all regulatory approvals in the Region, and performing the required post marketing clinical trials for BAQSIMI . During the term of the Agreement, Chengong is subject to minimum purchase amounts per contract year. Amphastar and Chengong will engage in profit sharing for any earnings above a certain floor price per unit, which will be determined using Chengong's per unit net revenue for BAQSIMI . Chengong has certain obligations with respect to the safety of data and quality control as set forth in a safety and data exchange agreement and quality agreement attached respectively as appendices to the Agreement and entered into in connection therewith. Each of Amphastar and Chengong have made customary representations, warranties and covenants in the Agreement. The term of the Agreement is for ten (10) years from the Effective Date and the parties may commence negotiations on an extension of the Agreement six (6) months prior to expiration. Both parties have termination rights without cause following the completion of the fourth (4 th ) Contract Year. Payments under the Agreement will be made in U.S. dollars. The total revenue of the Agreement to

Forward-Looking Statements

Forward-Looking Statements All statements in this current report that are not historical are forward-looking statements, including, among other things, statements relating to the performance of the parties under the Agreement and the expected payments thereunder. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including changes in laws and regulations and disruptions in supply chains as well as others described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 7, 2025. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this current report speak only as of the date of the report. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this current report to reflect events or circumstances in the future, even if new information becomes

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMPHASTAR PHARMACEUTICALS, INC. Date: October 24, 2025 By: /S/WILLIAM J. PETERS William J. Peters Chief Financial Officer, Executive Vice President and Treasurer